Intravenous administration of a single dose (20,ug) of recombinant interleukin-1-, to virgin, lactating and litter-removed rats rapidly decreased intestinal lipid absorption in all groups. In vivo, oxidation of ["4C]triolein to 14C02 was also significantly decreased by interleukin-1. In addition, the cytokine decreased [14C]lipid accumulation in the mammary gland of lactating rats and in the adipose tissue of virgin and litterremoved rats. The decrease in lipid uptake in the interleukin-treated rats was accompanied by hypertriglyceridaemia; however, there was no significant decrease in tissue lipoprotein lipase activity, except in heart from lactating rats. In contrast, interleukin-1 administration had no effect on lipogenesis in liver, white or brown adipose tissue of virgin rats fed on glucose. These results suggest that interleukin-1 profoundly affects lipid metabolism by delaying intestinal absorption and decreasing tissue uptake.
INTRODUCTION
Interleukin-1, primarily produced from phagocytic cells, is a polypeptide capable of mediating the host's responses to infection and inflammation (see Dinarello, 1984) . The physiological and metabolic effects that follow interleukin-I administration to experimental animals are varied and include fever (Dinarello & Wolff, 1982) , neutrophil activation (Kampschmidt, 1984) , B-and T-cell activation (Falkoff et al., 1983; Mizel, 1982) , enhanced liver protein synthesis (Pepys & Baltz, 1983) and amino acid release from skeletal muscle (Baracos et al., 1983) . Studies in vitro have also shown the ability of interleukin-I to decrease lipoprotein lipase activity in cultured 3T3-L1 adipocytes by inhibiting the synthesis of the enzyme (Price et al., 1986) . Little is known of the effects of interleukin-I in vivo on lipid metabolism. We have therefore studied the effects of acute interleukin-I administration on the utilization of dietary lipid ([W4C] triolein) in virgin, lactating and litter-removed rats.
Lactation was chosen as a model because it involves important changes in partitioning of dietary fat between mammary gland and adipose tissue (see Williamson, 1980 ; Vernon & Flint, 1983; Scow & Chernick, 1987) . Lactation decreases lipogenesis (Agius et al., 1979) , lipoprotein lipase (Hamosh et al., 1970; Flint et al., 1981) and lipid uptake (Oller do Nascimento & Williamson, 1986) in adipose tissue, but enhances metabolic activity in the mammary gland (Williamson, 1986) . The lactating mammary gland has increased rates of lipogenesis, increased lipoprotein lipase activity and lipid uptake. These tissue-specific changes in lipid metabolism are rapidly reversed on 'removal of the suckling litter (Williamson, 1980; Vernon & Flint, 1983 ; Oller do Nascimento & Williamson, 1986; Scow & Chernick, 1987 Nilsson-Ehle & Schotz (1976) . Lipoprotein lipase activity is expressed as nmol of fatty acid released/min per mg of acetone-dried powder. Post-heparin plasma lipolytic activity was measured in control and interleukin-treated virgin rats 20 min after intravenous injection (femoral vein) of 1000 units of heparin/kg body wt., in accordance with the procedure of Kuwajima et al. (1988) .
Measurement of lipogenesis
Lipogenesis in vivo was determined 5 h after the administration of either saline or interleukin-1. An intragastric glucose (4 mmol) load to stimulate lipogenesis (Agius & Williamson, 1980) was given 90 min before death of the rat. Lipogenic rate in vivo was determined with 3H20 as previously described (Robinson et al., 1978) . At I h before being killed, animals were injected with 0.3 ml (3.0 mCi) of 3H20 intraperitoneally; 5 min before death the animals were anaesthetized with pentobarbital (60 mg/kg body wt.). Tissues were saponified and fatty acids extracted by the method of Stansbie et al. (1976) . The amount of glucose load absorbed was measured as described by Mercer & Williamson (1987) . Blood metabolites and plasma insulin Whole-blood glucose was determined by the method of Slein (1963) and lactate by the method of Hohorst (1963) . Plasma triacylglycerol was measured by the method of Eggstein & Kreutz (1966) . Plasma glycerol was measured by the method of Garland & Randle (1962) , and plasma non-esterified fatty acids were measured with an enzymic colorimetric method (Wako Chemicals G.m.b.H, Neuss, West Germany). Plasma insulin was determined by radioimmunoassay with a rat insulin standard (Albano et al., 1972 (Table 1) . In lactating rats, interleukin-I caused a significant decrease (45°' ) in total mammary-gland accumulation, whereas in litterremoved rats, the effect of the cytokine was on adipose tissue (7000 decrease) ( Table 1) .
Gastrointestinal partitioning of the I"Cllipid
To see if the striking effects of interleukin-I on intestinal lipid absorption were related to altered gastrointestinal transit, the distribution of the ["4C]triolein between the stomach and the intestine was studied (Table  2) . In all control groups, 5 h after the administration of the tracer, most of the residual label (60-80 %) was already in the intestine, having left the stomach. Interleukin-1 reversed this pattern of distribution: most of the label was found in the stomach (58-70 0% ) of the treated animals. Similar results were found when the gastric and intestinal contents of glucose and lactate were measured after an oral load of glucuse (4 mmol) to virgin rats. Absorption of glucose from the intestinal tract was decreased from 74.3 00 + 5.9 (control group; n = 5) to 40.2%0±3.9 (treated group; n = 5). The distribution of glucose and lactate in the gastrointestinal tract was affected by interleukin-1 in a similar way to that of triolein (J. M. Argiles & F. J. Lopez-Soriano, unpublished work). It seems probable that the action of the cytokine upon absorption is to slow gastric transit, which, in turn, significantly affects nutrient uptake. Others have shown that another cytokine, tumour necrosis factor, inhibits gastric emptying (Patton et al., 1987) Robinson, 1970) , the activity was measured in white adipose tissue, mammary gland and heart (Table 3) . Although there was a tendency for interleukin-1 to Interleukin-1 and lipid metabolism (Price et al., 1986) and subsequent increased secretion of very-low-density lipoproteins from the liver.
Further support for these views is that plasma postheparin lipolytic activity, an index of heparin-releasable lipases, was significantly decreased (P < 0.05) in interleukin-treated virgin rats [341 + 66 (4) nmol of fatty acid released/min per ml of plasma, versus 523 + 10 (4) for control virgin rats]. Despite this evidence for impairment of functional lipoprotein lipase activity, plasma glycerol and plasma non-esterified fatty acids were not decreased by interleukin treatment (Table 3 ) and tended to be higher than the control values. As the two major potential sources of plasma glycerol and non-esterified fatty acids are the activities of lipoprotein lipase or hormone-sensitive triacylglycerol lipase in adipose tissue, the present evidence supports the view that there is increased lipolysis in adipose tissue in interleukin-treated rats. (Table 4) . Lipogenesis was not measured in the lactating group, because food availability modulates mammary-gland lipogenesis (Williamson et al., 1983) and the decreased intestinal absorption observed after interleukin-I treatment might influence the lipogenic rate of the mammary tissue in vivo (Mercer & Williamson, 1987) and be confused with an effect ot the cytokine.
Blood metabolites and plasma insulin Interleukin-I administration caused a tendency to hypoglycaemia in all experimental groups, but this was only significant in the lactating group (Table 5 ). Blood lactate concentrations were not altered by interleukin-I treatment. Interleukin-I tended to increase plasma insulin concentrations, leading to an increase in the insulin/ glucose ratio, but this was only significant in the virgin group. The effects in vitro of interleukin-I on insulin secretion from isolated rat pancreatic islets are variable, both inhibition and stimulation occurring depending on the experimental conditions (Comens et al., 1987) . The maintenance plasma insulin in the interleukin-1-treated rats suggests that changes in the concentration of the & Williamson, 1988) .
Comparison of effects of interleukin-1, tumour necrosis factor-a and tumour growth The present results and those of previous studies from this laboratory (Evans & Williamson, 1988a,b) allow a comparison to be made of the effects in vivo on lipid metabolism of the two related cytokines, interleukin-1 and tumour necrosis factor-a (cachectin), and of tumour growth (Table 6) . However, such comparisons must be viewed with some caution, because the dose of tumour necrosis factor was approx. 8-fold higher than that of interleukin-1, and the cytokines were only studied in the acute situation, whereas tumour burden was present for 8-10 days. The two cytokines had very similar effects on lipid metabolism, including decreased absorption, decreased oxidation, decreased deposition in white and brown adipose tissue and lactating mammary gland of an oral lipid load, and hypertriglyceridaemia. The major difference was that there was no significant decrease in measured lipoprotein lipase activity in interleukin-ltreated rats, although the effects on lipid metabolism of the cytokine suggested an impairment of the functional enzyme activity. The similarity of the effects of interleukin-1 and tumour necrosis factor on lipid metabolism (Table 6 ) suggest that they may act in concert in vivo. This view is strengthened by the finding that tumour necrosis factor can stimulate interleukin-1 secretion in vivo and in vitro (Bachwich et al., 1986; Dinarello et al., 1986) . The reverse is also true (Nawroth et al., 1986) . In contrast with the two cytokines, tumour growth itself did not alter lipid absorption or lipid accumulation in the lactating mammary gland (Evans & Williamson, 1988a) ; the effects on lipid metabolism appeared to be restricted to adipose tissue (Table 6 ). This explains the absence of hypertriglyceridaemia in tumour-bearing lactating rats (Evans & Williamson, 1988a deposition is depressed in adipose tissue and enhanced in mammary gland during lactation (Oller do Nascimento & Williamson, 1986) . Thus tumour growth, at least in the case of the Walker 256 carcinoma, appears to be more tissue-specific in its actions on lipid metabolism, which suggests that factors other than tumour necrosis factor or interleukin-1 may be involved in its effects.
